Trial Profile
Efficacy of Vernakalant in the conversion of atrial fibrillation in critical illness
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Vernakalant (Primary) ; Amiodarone
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Acronyms VINCES
- 20 Aug 2015 Status changed from recruiting to discontinued, as reported by Netherlands Trial Register (NTR4213)
- 19 Nov 2013 New trial record